StonvexLoading…
StonvexStonvexStonvexReal-time TradingView chart with full indicator set.
Last 7 days, powered by Finnhub. Tap Analyze to classify direction.
Loading latest news…
Pick the depth your tier unlocks. Logged-in Pro/Premium users automatically get the deeper report.
Free preview · 3 reports / hour · No sign-up required
Factor grades, AI Copilot, personalized ranking, and deeper event analysis.
Upgrade to Pro →Share this analysis with other traders
Disclaimer: The content on this page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consult a licensed financial advisor before making any investment decisions.
No sell-side coverage available for SIGA yet.
Common for small-cap names, ETFs, recent IPOs, and ADRs without US-listed sell-side coverage. When analysts publish, ratings appear here within one business day.
Earnings (▲ beat / ▼ miss) and ex-dividend dates plotted on the price line. Educational — proximity does not establish causation.
Indicator values from Polygon. Educational only — single- indicator triggers in isolation are not a complete trading signal.
| Date | Open | Close | Δ | Vol |
|---|---|---|---|---|
| 05-18 | $4.20 | $4.27 | +1.67% | 0.6M |
| 05-19 | $4.25 | $4.37 | +2.82% | 0.5M |
| 05-20 | $4.37 | $4.49 | +2.75% | 1.0M |
| 05-21 | $4.47 | $4.71 | +5.37% | 0.9M |
| 05-22 | $4.68 | $4.68 | +0.00% | 0.6M |
Documents are served directly from sec.gov / the issuer's website — Stonvex does not proxy or store filings.
SIGA Technologies Inc a commercial-stage pharmaceutical company. The Company sells its product, TPOX oral TPOXX, also known as tecovirimat, Tecovirimat-SIGA, or TEPOXX (tecovirimat) in certain international markets, to the U.S. Government and international governments (including government-affiliated entities). The Company operates in one single operating and reportable segment, which includes all activities related to the sale of the Company's Oral and IV TPOXX as well as research and development services.
Aggregated from Polygon's per-article sentiment classifications. Educational — sentiment is descriptive, not predictive.
Quarterly filings sourced directly from SEC EDGAR. Real-time earnings actuals are in the Earnings panel above.
| Metric | Q1 2026 2026-03-31 | Annual 2025 2025-12-31 | Q3 2025 2025-09-30 | Q2 2025 2025-06-30 |
|---|---|---|---|---|
Revenue | $6.24M | $94.57M | $90.78M | $88.16M |
Operating Income | $-5.32M | $23.70M | $33.20M | $43.42M |
Net Income | $-3.45M | $23.28M | $28.71M | $35.07M |
EPS (Diluted) | $-0.05 | $0.32 | $0.40 | $0.49 |
Total Assets | $219.39M | $219.47M | $231.60M | $235.33M |
Total Liabilities | $67.77M | $20.65M | $28.12M | $26.02M |
Cash & Equivalents | $145.56M | $154.97M | $171.96M | $182.46M |
Free Cash Flow OCF − CapEx | $-8.66M | $43.12M | $60.02M | $70.12M |
Shares Outstanding | 71.72M | 71.61M | 71.61M | 71.54M |
Latest Form 13F-HR disclosures from the curated Super Investors list. Click through to see each manager's full long book.